VivoSim Labs Presents NAMs Data

VivoSim Labs announced groundbreaking data at the European Society of Endocrinology's annual conference in Netherlands — Maastricht, Netherlands, showcasing the superior predictive power of its AI-enabled NAMkind Liver and NAMkind GI platforms. These 3D human tissue models demonstrate over 90% sensitivity in detecting liver toxicity and fewer than 5% false positives, significantly outperforming traditional animal models. This development is crucial for the pharmaceutical industry, which is shifting away from animal testing due to encouragement from the United States — Food and Drug Administration. VivoSim Labs's technology helps clients avoid costly mistakes in drug development, potentially saving $50M - $200M per missed drug candidate. The models are effective for both small molecules and complex Antibody Drug Conjugates (ADCs), offering high accuracy in predicting clinical outcomes for liver and gastrointestinal toxicity. Key figures like Keith Murphy and Amar Sethi from VivoSim Labs highlighted the importance of these human-relevant models in predicting risk and guiding safer drug design.